Accropeutics’ Oral Selective TYK2/JAK1 Inhibitor Performs Well in Phase 2 Study of Moderate-to-Severe Plaque PsO May 21, 2025
Residual Inflammation in Psoriasis Linked to Obesity, Fatty Liver Disease: Exploring Implications for Treatment May 20, 2025
Personalized Medicine in Psoriasis: Mindera Health’s Mind.Px Test Changes Physician Behavior, Improves Outcomes May 13, 2025
PsO Pipeline Watch: Oral IL-23 Blocker Icotrokinra Produces Significant Skin Clearance in Patients with Scalp and Genital PsO May 9, 2025
2025 SID Annual Meeting Coverage: Artax Biopharma’s Oral Nck Modulator Shows Promise in PsO May 9, 2025
As PDUFA Data Nears, Roflumilast Foam 0.3% (Zoryve, Arcutis) Improves Scalp and Body Pso Symptoms, Including Itch, in Phase 3 Study May 7, 2025
Topline Phase 3 Data: Guselkumab (Tremfya, Janssen Pharmaceuticals) Cools Inflammation and Halts Disease Progression in PsA April 7, 2025
A Bridge Over Troubled Water: Art Garfunkel Opens Up About Finding the Right PsO Treatment as Part of New Partnership With Sun Pharma April 4, 2025
The Search for Steroid-sparing Options in PsO: PEPITEM and Its Tripeptide Sequence Shows Promise April 3, 2025
